| P50 | author | Yi-Hsiang Huang | Q41050730 |
| | Po-hong Liu | Q42832773 |
| | Chien-Wei Su | Q49046110 |
| P2093 | author name string | Han-Chieh Lin | |
| | Teh-Ia Huo | |
| | Cheng-Yuan Hsia | |
| | Chia-Yang Hsu | |
| | Yi-You Chiou | |
| | Yun-Hsuan Lee | |
| P2860 | cites work | Staging for hepatocellular carcinoma: complex and confusing | Q87779427 |
| | Hepatocellular carcinoma: have we finally found the ultimate staging system for HCC? | Q87815054 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 |
| | Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach | Q29614698 |
| | Management of hepatocellular carcinoma | Q29616230 |
| | Hepatocellular carcinoma | Q29616359 |
| | Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 |
| | Prognosis of hepatocellular carcinoma: the BCLC staging classification | Q29619984 |
| | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma | Q30479629 |
| | Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. | Q30512830 |
| | Percutaneous ablation therapy for hepatocellular carcinoma: current practice and future perspectives | Q33214340 |
| | A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems | Q33721747 |
| | Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome | Q34207805 |
| | Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade | Q35065472 |
| | Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. | Q35107166 |
| | Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. | Q35597241 |
| | Epidemiology of hepatocellular carcinoma: consider the population | Q36930514 |
| | Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis | Q37440707 |
| | Current strategy for staging and treatment: the BCLC update and future prospects. | Q37696399 |
| | Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib | Q37995993 |
| | Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models | Q39861863 |
| | Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. | Q41746298 |
| | A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients | Q42203185 |
| | Is there an ideal prognostic model for hepatocellular carcinoma? | Q43004242 |
| | Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. | Q43174194 |
| | Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. | Q44885846 |
| | A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery | Q45166388 |
| | Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma | Q45402508 |
| | Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma ≤ 2 cm in a Propensity Score Model | Q48095524 |
| | Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. | Q51541140 |
| | Key Concepts in Model Selection: Performance and Generalizability. | Q52080616 |
| | Survival Advantage of Radiofrequency Ablation Over Transarterial Chemoembolization for Patients with Hepatocellular Carcinoma and Good Performance Status Within the Milan Criteria | Q58576422 |
| | The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? | Q79363825 |
| | Comparing Cox regression and parametric models for survival of patients with gastric carcinoma | Q80410987 |
| | The role of transcatheter arterial embolization for patients with unresectable hepatocellular carcinoma: a nationwide, multicentre study evaluated by cancer stage | Q81531606 |
| | Hepatitis B virus infection | Q83352950 |
| | A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System | Q84184317 |
| | Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort | Q85261942 |
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | e1772 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology | |
| P478 | volume | 94 | |